Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 23rd Preview)
-
Regulatory approvals in oncology
The FDA approved datopotamab deruxtecan (Datroway/Dato-DXd) for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy. The decision is based on the phase 3 TROPION-Breast02 trial (NCT05374512), where the antibody-drug conjugate improved overall survival and progression-free survival versus investigator’s-choice chemotherapy. Across the pivotal data set, Dato-DXd achieved a median OS of 23.7 months versus 18.7 months with chemotherapy (HR 0.79; P=0.0290). The trial also showed a 43% reduction in risk of progression or death (HR 0.57) and higher objective response rates (64% vs 30%). The approval expands TROP2-directed treatment options in a difficult-to-treat setting. Separately, the FDA granted a key approval for Datroway as a first-line option for triple-negative breast cancer, marking another regulatory milestone for the program and reinforcing its positioning relative to competing ADC strategies. Together, these approvals may influence sequencing decisions for frontline TNBC therapies in patients ineligible for immunotherapy.
-
Phase 3 ADC readouts in lung cancer
A phase 3 study in China gave sacituzumab tirumotecan (sac-TMT) a randomized edge over Keytruda (pembrolizumab) in treatment-naïve, PD-L1–positive non-small cell lung cancer. In the OptiTROP-Lung05 abstract ahead of ASCO 2026, the TROP2-directed ADC plus Keytruda cut the risk of disease progression or death by 65% versus Keytruda alone. The progression-free survival results were reported as statistically significant (p<0.0001) with median PFS not reached in the combination arm after a median follow-up of 10.5 months, compared with 5.7 months for Keytruda monotherapy. A preliminary survival signal also favored the combo, though overall survival data were not mature at the stated cutoff. The readout increases pressure on alternative frontline strategies, including PD-(L)1xVEGF bispecifics, as developers race to define a new standard in a lucrative immuno-oncology segment. Keytruda’s baseline performance appears consistent across studies, sharpening attention on the ADC’s incremental effect size as the field heads deeper into ASCO 2026.
-
Cell therapy engineering in solid tumors
Researchers at UCLA Health reported preclinical data suggesting a new “cytokine-armored” CAR T design could better handle antigen heterogeneity and immunosuppression in glioma models. The approach reprogrammed CAR T cells to release IL-12 and DR-18, aiming to amplify innate and adaptive immune activation within tumors. In mouse studies, the armored CAR T therapy improved tumor control and reduced dangerous side effects that can limit CAR T deployment in brain cancer. The team also reported synergy when pairing the approach with a second CAR T strategy targeting VEGF, maintaining anti-tumor activity while mitigating tolerability concerns. The work, published in Cancer Research, targets recurring limitations in solid-tumor CAR T development—variable antigen expression and a suppressive tumor microenvironment. While still preclinical, the cytokine “arming” strategy may inform the next generation of translational designs for high-grade gliomas.
-
Gene-editing translation and regulatory posture
University of Pennsylvania investigators and Children’s Hospital of Philadelphia clinicians reported meaningful clinical benefits after an mRNA-based CRISPR base-editing treatment for an infant with CPS1 deficiency, while emphasizing the intervention was not a trial. Lead investigators Kiran Musunuru and Rebecca Ahrens-Nicklas framed the case as expanded access clinical care rather than a scientifically powered study. In statements highlighted around the patient’s progress—including ability to eat a normal protein-filled diet—Musunuru argued that the regulatory and evidentiary framework must keep pace with fast-moving genome editing capabilities. The comments place the case within a broader competition among base-editing developers pushing toward clinical trial programs. For the sector, the messaging underscores how regulators may evaluate safety and efficacy evidence differently for single-patient expanded access experiences versus formal clinical trials, even when outcomes appear promising.
-
FDA action on targeted hepatitis D therapy
The FDA cleared Gilead’s hepatitis D treatment Hepcludex (bulevirtide) nearly four years after an earlier rejection. The first decision in this approval cycle reportedly hinged on manufacturing and distribution issues, which the agency previously flagged before it would authorize the drug. With the new clearance, bulevirtide becomes an approved option for chronic hepatitis D, addressing an unmet need where limited therapies have historically constrained clinical management. The approval also signals that regulatory focus on chemistry, manufacturing, and distribution can be a gating factor even after initial clinical development progress. For Gilead and the broader liver-disease market, the action may accelerate uptake of targeted entry inhibition strategies and increase competitive pressure for next-generation hepatitis D regimens.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.